Urinary bladder cancer characteristics prognosis review conflicts of interest with respect to the research authorship and/or publication of this article.

Biopsy/methods Carcinoma in Situ/*pathology/*therapy Humans Muscle Smooth Neoplasm Invasiveness Urinary Bladder Neoplasms/*pathology/therapy Biopsias aleatorias de vejiga Carcinoma in situ Non-muscle invasive bladder cancer Random bladder biopsies Tumor vesical no-músculo invasivo

Bacille Calmette-Guérin Nmibc gemcitabine intravesical therapy meta-analysis non-muscle invasive bladder cancer

prostate cancer radiation radical prostatectomy radiotherapy secondary bladder cancer

Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

bladder tumor childhood exposure environmental smoking nonsmoking adult

*Cystectomy *Health Status Humans Patient Education as Topic/*methods Preoperative Care/*methods Relaxation Therapy/*methods Urinary Bladder Neoplasms/*surgery Bladder cancer Cystectomy Supportive intervention Systematic review PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Depression anxiety bladder cancer prevalence systematic review

Circulating Tumor DNA/*analysis/blood/urine Humans Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/pathology CfDNA biomarkers diagnosis meta-analysis

bladder cancer hydronephrosis lymph node invasion stage survival

Cystectomy/*methods Humans *Robotic Surgical Procedures Treatment Outcome Urinary Bladder Neoplasms/*surgery Oncologic outcome Open radical cystectomy Positive surgical margin Robot-assisted radical cystectomy

Aminolevulinic Acid/*chemistry Cystoscopy/methods Humans Image Interpretation Computer-Assisted/*methods Narrow Band Imaging/methods Photosensitizing Agents/*chemistry Urinary Bladder Neoplasms/metabolism/pathology/*surgery Narrow band imaging bladder cancer diagnostic performance photodynamic diagnosis white light-guided cystoscopy

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Periodontal diseases cohort studies meta-analysis periodontitis urinary bladder neoplasms

Blood Loss Surgical *Cystectomy Diet Humans Lymph Nodes/pathology *Minimally Invasive Surgical Procedures Postoperative Complications/etiology Randomized Controlled Trials as Topic Recurrence Treatment Outcome Urinary Bladder Neoplasms/*surgery Open radical cystectomy laparoscopic radical cystectomy meta-analysis minimally invasive randomized controlled trials robot-assisted radical cystectomy

Administration Intravesical Antineoplastic Agents/*administration & dosage Humans Infusions Intra-Arterial Meta-Analysis as Topic Systematic Reviews as Topic Urinary Bladder Neoplasms/*drug therapy

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

*Conversion to Open Surgery *Cystectomy Humans Odds Ratio Operative Time Postoperative Complications/etiology *Robotic Surgical Procedures Treatment Outcome Urinary Bladder Neoplasms/*surgery complications meta-analysis open radical cystectomy robotic